Valaciclovir update

Advances in Experimental Medicine and Biology

Volumn 458, Issue , 1999, Pages 149-157

  Bell, A R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ACICLOVIR DERIVATIVE; VALACICLOVIR; ZELITEX;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; FLU LIKE SYNDROME; GENITAL HERPES; HEADACHE; HERPES VIRUS INFECTION; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; RECURRENT INFECTION; RHINITIS;

CYTOMEGALOVIRUS; GEOCORIS; HERPES; HERPES ZOSTER; HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033281855     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4743-3_14     Document Type: Conference Paper

References (31)

1. Purification and characterisation of a rat liver enzyme that hydrolyses valaciclovir, the L-valyl ester prodrug of aciclovir
2. Pharmacokinetics of the aciclovir prodrug valaciclovir after escalating single- and multiple-dose administration to normal volunteers
3. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy
4. Pharmacokinetics of 256U87, an aciclovir prodrug, in renal transplant patients
5. Phase I trial of valaciclovir, the L-valyl ester of aciclovir, in patients with advanced human immunodeficiency virus disease
6. Valtrex (valaciclovir) - Bioavailability in different patient populations
7. Valaciclovir: Development, clinical utility and potential
8. Valaciclovir HCl (Valtrex): An aciclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster
9. Valaciclovir compared with aciclovir for improved therapy for herpes zoster in immunocompetent adults
10. How should zoster trials be conducted?
11. Comparison of valaciclovir and aciclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: A cost-consequence model
12. Oral aciclovir in herpes zoster ophthalmicus
13. A double blind randomised trial to compare the safety and efficacy of valaciclovir and aciclovir for treatment of herpes zoster ophthalmicus
14. Valaciclovir for the treatment of herpes zoster - Influence of patient age and dermatome
15. The nature of herpes zoster: A long-term study and a new hypothesis
16. The natural history of herpes zoster
17. The current trend in genital herpes. Progress in prevention
18. Herpes simplex virus type 2 in the United States, 1976 to 1994
19. Valaciclovir versus aciclovir in the treatment of first-episode genital herpes infection
20. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis
21. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomised, double blind clinical trial
22. A randomised, placebo-controlled comparison of oral valaciclovir and aciclovir in immunocompetent patients with recurrent genital herpes infections
23. Prevention of lesion development in recurrent genital herpes with oral valaciclovir
24. Valaciclovir for the suppression of recurrent genital HSV infection: A placebo controlled study of once daily therapy
25. A comparative trial of valaciclovir, aciclovir and placebo for the suppression of genital herpes infection in immunocompetent patients
26. Valaciclovir for prevention of recurrent herpes simplex virus infection in HIV infected individuals - A double-blind controlled trial
27. A randomised, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection
28. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus disease in a cytomegalovirus prophylaxis trial (ACTG 204)
29. Long-term safety of valaciclovir for suppression of herpes simplex virus infections
30. Efficacy and safety of valaciclovir for suppression of cytomegalovirus disease in recipients of a cadaveric renal allograft